JP5153870B2 - カルボスチリル誘導体およびドネペジルを含むアルツハイマー病治療剤 - Google Patents

カルボスチリル誘導体およびドネペジルを含むアルツハイマー病治療剤 Download PDF

Info

Publication number
JP5153870B2
JP5153870B2 JP2010509026A JP2010509026A JP5153870B2 JP 5153870 B2 JP5153870 B2 JP 5153870B2 JP 2010509026 A JP2010509026 A JP 2010509026A JP 2010509026 A JP2010509026 A JP 2010509026A JP 5153870 B2 JP5153870 B2 JP 5153870B2
Authority
JP
Japan
Prior art keywords
salt
donepezil
alzheimer
therapeutic agent
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010509026A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010527993A (ja
JP2010527993A5 (enExample
Inventor
平伊 新井
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Juntendo University
Original Assignee
Otsuka Pharmaceutical Co Ltd
Juntendo University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd, Juntendo University filed Critical Otsuka Pharmaceutical Co Ltd
Priority to JP2010509026A priority Critical patent/JP5153870B2/ja
Publication of JP2010527993A publication Critical patent/JP2010527993A/ja
Publication of JP2010527993A5 publication Critical patent/JP2010527993A5/ja
Application granted granted Critical
Publication of JP5153870B2 publication Critical patent/JP5153870B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2010509026A 2007-05-22 2008-05-21 カルボスチリル誘導体およびドネペジルを含むアルツハイマー病治療剤 Expired - Fee Related JP5153870B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2010509026A JP5153870B2 (ja) 2007-05-22 2008-05-21 カルボスチリル誘導体およびドネペジルを含むアルツハイマー病治療剤

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2007135367 2007-05-22
JP2007135367 2007-05-22
JP2010509026A JP5153870B2 (ja) 2007-05-22 2008-05-21 カルボスチリル誘導体およびドネペジルを含むアルツハイマー病治療剤
PCT/JP2008/059763 WO2008143361A1 (en) 2007-05-22 2008-05-21 A medicament comprising a carbostyril derivative and donepezil for treating alzheimer's disease

Publications (3)

Publication Number Publication Date
JP2010527993A JP2010527993A (ja) 2010-08-19
JP2010527993A5 JP2010527993A5 (enExample) 2011-01-27
JP5153870B2 true JP5153870B2 (ja) 2013-02-27

Family

ID=39636992

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010509026A Expired - Fee Related JP5153870B2 (ja) 2007-05-22 2008-05-21 カルボスチリル誘導体およびドネペジルを含むアルツハイマー病治療剤

Country Status (27)

Country Link
US (1) US20100298375A1 (enExample)
EP (2) EP2937085B1 (enExample)
JP (1) JP5153870B2 (enExample)
KR (1) KR101441725B1 (enExample)
CN (1) CN101754758B (enExample)
AR (1) AR066664A1 (enExample)
AU (1) AU2008253977B2 (enExample)
BR (1) BRPI0811919A2 (enExample)
CA (1) CA2687289C (enExample)
CO (1) CO6251249A2 (enExample)
CY (1) CY1116683T1 (enExample)
DK (1) DK2157973T3 (enExample)
ES (1) ES2545959T3 (enExample)
HR (1) HRP20150843T1 (enExample)
HU (1) HUE025902T2 (enExample)
IL (1) IL202053A (enExample)
MX (1) MX2009012583A (enExample)
MY (1) MY146407A (enExample)
NZ (1) NZ581099A (enExample)
PL (1) PL2157973T3 (enExample)
PT (1) PT2157973E (enExample)
RU (1) RU2469723C2 (enExample)
SI (1) SI2157973T1 (enExample)
TW (2) TWI423802B (enExample)
UA (1) UA96633C2 (enExample)
WO (1) WO2008143361A1 (enExample)
ZA (1) ZA200908202B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2135607A1 (en) 2008-06-18 2009-12-23 Pharnext Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
US9387206B2 (en) 2009-11-03 2016-07-12 Pharnext Therapeutic approaches for treating Alzheimer's disease
EP2322163A1 (en) * 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
SI2560631T1 (sl) 2011-03-01 2014-06-30 Pharnext Na baklofenu in akamprosatu temeljeäśa terapija nevroloĺ kih nepravilnosti
US9241933B2 (en) 2011-03-01 2016-01-26 Pharnext Compositions for treating amyotrophic lateral sclerosis
US10010515B2 (en) 2011-03-01 2018-07-03 Pharnext Therapeutic approaches for treating Parkinson's disease
US9248111B2 (en) 2011-03-01 2016-02-02 Pharnext Therapeutic approaches for treating parkinson's disease
MX2014015310A (es) 2012-06-15 2015-07-06 Found Biomedical Res & Innov Agente profilactico y/o terapeutico para el deterioro cognoscitivo leve.
WO2015100255A2 (en) * 2013-12-23 2015-07-02 Holaday John W Disposable container for air hydration
CN109310688B (zh) 2016-05-19 2023-09-01 国立研究开发法人国立循环器病研究中心 用于预防和/或治疗痴呆症的药物
HUE053636T2 (hu) 2017-05-24 2021-07-28 H Lundbeck As 5-HT6 receptor antagonista és acetilkolin-észteráz inhibitor kombinációja Alzheimer-kór kezelésében történõ alkalmazásra ApoE4 alléleket hordozó betegek szubpopulációjában
CN107602523B (zh) * 2017-09-11 2020-08-18 安徽中医药大学 京尼平类似物、制备方法及其应用
PL237739B1 (pl) 2018-06-06 2021-05-17 Univ Gdanski Genisteina do zastosowania do leczenia choroby Alzheimera
NL2024431B1 (en) 2019-12-11 2021-09-07 Sulfateq Bv Compounds for treatment of alzheimer’s disease
CN117797095A (zh) * 2023-11-30 2024-04-02 浙江大学 一种长效脂质液晶植入物及其治疗阿尔茨海默症的用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5535019A (en) * 1978-09-01 1980-03-11 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
JPS5649378A (en) 1979-08-25 1981-05-02 Otsuka Pharmaceut Co Ltd Tetrazolylalkoxycarbostyril derivative
FI95572C (fi) 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
JP2574099B2 (ja) 1992-05-21 1997-01-22 大塚製薬株式会社 アレルギー疾患治療剤
JPH10175864A (ja) 1996-12-16 1998-06-30 Otsuka Pharmaceut Co Ltd 慢性閉塞性肺疾患治療剤
US6428488B1 (en) * 1997-08-28 2002-08-06 Kenneth Kensey Dual riser/dual capillary viscometer for newtonian and non-newtonian fluids
US6322525B1 (en) * 1997-08-28 2001-11-27 Visco Technologies, Inc. Method of analyzing data from a circulating blood viscometer for determining absolute and effective blood viscosity
US6019735A (en) * 1997-08-28 2000-02-01 Visco Technologies, Inc. Viscosity measuring apparatus and method of use
US6322524B1 (en) * 1997-08-28 2001-11-27 Visco Technologies, Inc. Dual riser/single capillary viscometer
WO1999036405A1 (en) * 1998-01-16 1999-07-22 Eisai Co., Ltd. Process for production of donepezil derivative
US6187790B1 (en) * 1999-03-04 2001-02-13 Neal R. Cutler Use of cilostazol for treatment of sexual dysfunction
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6484565B2 (en) * 1999-11-12 2002-11-26 Drexel University Single riser/single capillary viscometer using mass detection or column height detection
US6458804B1 (en) * 2001-01-26 2002-10-01 R.T. Alamo Venturesi, Llc Methods for the treatment of central nervous system disorders in certain patient groups
TW200301135A (en) * 2001-12-27 2003-07-01 Otsuka Maryland Res Inst Inc Pharmaceutical compositions comprising a multifunctional phosphodiesterase inhibitor and an adenosine uptake inhibitor
IL150509A (en) * 2002-07-01 2007-07-04 Joseph Kaspi Pharmaceutical preparations containing donafazil hydrochloride
US6743806B2 (en) * 2002-10-23 2004-06-01 Otsuka Pharmaceutical Company, Limited Active oxygen scavenger
FR2848452B1 (fr) * 2002-12-12 2007-04-06 Aventis Pharma Sa Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer
JP2004189706A (ja) * 2002-12-13 2004-07-08 Eisai Co Ltd 高度アルツハイマー型痴呆治療剤
TWI323660B (en) * 2003-02-25 2010-04-21 Otsuka Pharma Co Ltd Pten inhibitor or maxi-k channels opener

Also Published As

Publication number Publication date
NZ581099A (en) 2012-03-30
HUE025902T2 (en) 2016-05-30
MX2009012583A (es) 2010-03-08
EP2937085A1 (en) 2015-10-28
EP2937085B1 (en) 2019-07-10
CN101754758A (zh) 2010-06-23
RU2469723C2 (ru) 2012-12-20
CY1116683T1 (el) 2017-03-15
RU2009147456A (ru) 2011-06-27
WO2008143361A1 (en) 2008-11-27
PL2157973T3 (pl) 2015-12-31
TWI423802B (zh) 2014-01-21
CO6251249A2 (es) 2011-02-21
HK1215384A1 (en) 2016-08-26
HRP20150843T1 (hr) 2015-09-11
SI2157973T1 (sl) 2015-10-30
AU2008253977B2 (en) 2013-08-22
ES2545959T3 (es) 2015-09-17
KR101441725B1 (ko) 2014-09-18
DK2157973T3 (en) 2015-08-17
KR20100020482A (ko) 2010-02-22
CA2687289C (en) 2015-09-15
PT2157973E (pt) 2015-10-14
ZA200908202B (en) 2010-07-28
BRPI0811919A2 (pt) 2014-11-18
TWI489983B (zh) 2015-07-01
US20100298375A1 (en) 2010-11-25
EP2157973B1 (en) 2015-07-15
JP2010527993A (ja) 2010-08-19
AU2008253977A1 (en) 2008-11-27
HK1140422A1 (en) 2010-10-15
CN101754758B (zh) 2012-10-24
IL202053A0 (en) 2010-06-16
EP2157973A1 (en) 2010-03-03
IL202053A (en) 2016-04-21
UA96633C2 (uk) 2011-11-25
CA2687289A1 (en) 2008-11-27
MY146407A (en) 2012-08-15
AR066664A1 (es) 2009-09-02
TW201412315A (zh) 2014-04-01
TW200904428A (en) 2009-02-01

Similar Documents

Publication Publication Date Title
JP2010527993A (ja) カルボスチリル誘導体およびドネペジルを含むアルツハイマー病治療剤
JP2014185161A (ja) シロスタゾールを含むカルボスチリル誘導体の脂肪肝治療剤
US20160009658A1 (en) Hydantoins that modulate bace-mediated app processing
US10844071B2 (en) Substituted [1,2,3]triazolo[4,5-d]pyrimidines that lower stress-induced p-tau
JPH0820531A (ja) 緑内障治療剤及び眼圧降下剤
EP1741430B1 (en) Remedy for psychoneurotic diseases
JP2026503810A (ja) ブンタネタプおよびその類似体の投与を介する精神病の処置
HK1215384B (en) A medicament comprising a carbostyril derivative and donezepil for treating alzheimer's disease
HK1140422B (en) A medicament comprising a carbostyril derivative and donepezil for treating alzheimer's disease
CA2678920C (en) A medicament for treating chronic obstructive pulmonary disease
HK1140136B (en) A medicament for treating chronic obstructive pulmonary disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101130

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20121106

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20121204

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20151214

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 5153870

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees